Capital with purpose: How capital markets are shaping the future of medicine with Dheeraj Chinthalapelly

With a career spanning over a decade and a half in global capital markets and working in Sydney, Mumbai, London, and New York, Dheeraj Chinthalapelly has built a career at the intersection of finance, science, and management. From navigating global financial markets to helping innovative biotechnology companies foster drug development, he has helped healthcare companies navigate critical inflection points, raising billions in capital and executing transformative mergers and acquisitions (M&A) transactions and thereby impacting patient lives.

US Biotech markets remain one of the most sophisticated markets in the world and serve as the financial engine for scientific progress. The industry is navigating a challenging phase, shaped by policy uncertainty, rapid innovation in major disease areas, such as obesity and immunology, the accelerating use of AI in R&D, the rise of China’s biotech sector, and shifting capital allocation trends.

In this conversation, Chinthalapelly reflects on the ever-changing industry landscape, his journey, the lessons from advising the companies in this ecosystem, and the purpose that drives his work today.


From global capital markets to the forefront of biotech investment banking, please share key insights into your professional journey and what drives the work you do now.

My professional journey has been extremely enriching, providing me with an opportunity to work with immensely talented people across the world and gain valuable learning experiences along the way.

I began my professional career in Sydney in Sales and Trading and covered the Australian and Hong Kong markets as an option trader. It was a fast-paced and dynamic environment, where I not only gained a deep understanding of financial products but also learnt the key drivers of business across the mining and financial sectors. Thereafter, I worked with Nomura in Structured Credit and gained a deep understanding of European credit markets. I realised I enjoyed collaborating with the management to shape the company’s strategy and support their growth. That led me to pursue an MBA at the NYU Stern School of Business and transition to Investment Banking. Today, I serve as a Director at Truist Securities in the Healthcare Investment Banking Group, where I advise public and private biotechnology companies. In this role, I combine my deep expertise in finance, strategy, and a passion for science to contribute to something larger, helping bring new, differentiated therapies to patients.

What was it that pulled you specifically toward the healthcare sector?

Healthcare is personal for me. I come from a family of healthcare professionals, and I have always seen it as a field where financial expertise can serve a purpose far greater than returns alone. The companies I advise are developing therapies that either redefine the standard of care for patients or bring first-in-class treatments to those who currently have none. When I help a biotech company raise capital at a critical inflection point in its development, that capital has a direct line to patients, sometimes thousands of them, in diseases where no alternative exists. It is that combination of intellectual complexity and tangible human impact that makes this sector unlike anything else in finance.

Q: What are the most transformative transactions you have worked on?

A few stand out. A transaction I am proud of is helping a large biotechnology company purchase a strategic asset in the heme-oncology therapeutic area, where currently no drug is available beyond chemotherapy. Executing this transaction meant not only bringing the drug to thousands of patients but also expanding the reach globally with the acquirer’s commercial franchise. This was one of those transactions where the purposeful impact of my work is visible first-hand.

Q: How has the biotech capital markets landscape evolved in recent years?

The biotech capital markets have undergone a fundamental reset since the peak of the COVID era. The current environment is characterised by disciplined investment, one shaped not only by macroeconomic forces but by a shifting policy landscape and the ongoing uncertainty surrounding the FDA. Generalist investors have largely stepped back, and the capital that remains is predominantly specialist in nature, and it is being deployed with considerably greater scrutiny. Private financing rounds today are increasingly reserved for companies that have demonstrably de-risked their lead assets, secured the backing of marquee institutional investors, and can point to near-term value inflection catalysts. The bar has risen meaningfully, but for companies that meet it, capital remains accessible and the market remains open.

Q: What is your approach to advising biotech companies considering an IPO in today's environment?

A. Start early. Relationships with investors and advisors need to be built well before you are formally in the market. Selecting your shareholders carefully is critical - the quality of your investor base matters far more than maximising short-term valuation. And never lose sight of your cash position. A cash runway is the one asset that keeps all your other options alive. Most importantly, I always remind management teams that an IPO is a beginning, not an ending. The discipline, transparency, and long-term thinking required to succeed as a public company are considerably greater than what it takes to get there.

Q: Your career spans from trading floors to healthcare investment banking across multiple continents. What does that breadth look like in practice, and what keeps you motivated in this work?

A. The diversity of my experience is something I genuinely value and has made me a better advisor. I have worked with healthcare companies at every stage of their lifecycle, from pre-revenue startups navigating their first institutional financing to multi-billion-dollar public companies executing transformative M&A. Each engagement is different and presents a unique set of challenges and strategic considerations. Regulatory environments, market maturity, investor expectations, business model, all of these variables shift the analysis significantly, and that constant intellectual recalibration is something I find deeply engaging.

What drives me is the combination of curiosity and consequence. I am drawn to complex systems, how they function, where they break down, and how they can be made to work better. Healthcare investment banking puts that curiosity to work in an industry where the stakes are high. The people I advise are making decisions that will determine whether a new therapy reaches patients. If I can help a company secure the capital it needs to bring a life-changing therapy to patients, that is incredibly fulfilling, and it is what keeps me showing up with purpose every day.

Q: What advice would you give to someone aspiring to follow a similar path?

A. Be curious about the sector and keep an open mind. This career rewards people who show up consistently, keep learning long after they think they have stopped needing to, and remain honest about what they do not yet know. The world is full of opportunities if you show up prepared and are willing to put in the work.

This article has been authored by Priyanka Chaki

Disclaimer: The above content is non-editorial, and TIL hereby disclaims any and all warranties, expressed or implied, relating to it, and does not guarantee, vouch for or necessarily endorse any of the content.